{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:44Z","timestamp":1781632484293,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["15964\/15964.01; and 17783."],"award-info":[{"award-number":["15964\/15964.01; and 17783."]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      We investigated serotonergic and dopaminergic terminal integrity role in\n                      <jats:italic>PRKN-<\/jats:italic>\n                      associated Parkinsonism (PRKN-PD) using [\u00b9\u00b9C]DASB Positron Emission Tomography (PET) and [\u00b9\u00b2\u00b3I]FP-CIT Single Photon Emission Computerised Tomography (SPECT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fourteen PRKN-PD patients (mean age 49.70\u2009\u00b1\u200910.83, disease duration 10.95\u2009\u00b1\u20097.59 years, H&amp;Y 2.0\u2009\u00b1\u20090.68), and twelve iPD patients (mean age 65.40\u2009\u00b1\u20097.48 years, disease duration 5.05\u2009\u00b1\u20094.50 years, H&amp;Y 2.0\u2009\u00b1\u20090.93) underwent clinical assessments, 3-Tesla MRI, [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB PET-CT, and [\n                      <jats:sup>123<\/jats:sup>\n                      I]FP-CIT SPECT, and compared with previously acquired healthy control (HCs) data. [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB distribution volume ratio (DVR) parametric images were generated and DVR-1 values, equivalent to BP\n                      <jats:sub>ND<\/jats:sub>\n                      , sampled from a priori selected regions-of-interest (ROIs) with the posterior cerebellum as reference. [\n                      <jats:sup>123<\/jats:sup>\n                      I]FP-CIT images underwent reconstruction and normalization to standard space, and striatal Specific Binding Ratio (SBR) calculated from the eight hottest consecutive slices.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PRKN-PD patients showed 20.8% to 45.2% [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB BP\n                      <jats:sub>ND<\/jats:sub>\n                      loss across several cortical and subcortical ROIs compared to HCs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.01). After adjusting for age and disease duration, no differences in [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB BP\n                      <jats:sub>ND<\/jats:sub>\n                      were observed between PRKN-PD and iPD. In PRKN-PD, higher [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB BP\n                      <jats:sub>ND<\/jats:sub>\n                      in the raphe, brainstem, ventral striatum, and amygdala, correlated with higher scores on the Non-Motor Symptoms Scale (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Higher [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB BP\n                      <jats:sub>ND<\/jats:sub>\n                      in the caudate and putamen correlated with higher scores on the Beck Depression Inventory II scale (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). No correlation was detected between [\n                      <jats:sup>11<\/jats:sup>\n                      C]DASB BP\n                      <jats:sub>ND<\/jats:sub>\n                      and [\n                      <jats:sup>123<\/jats:sup>\n                      I]FP-CIT SBR in the caudate and putamen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PRKN-PD is characterized by widespread serotonergic dysfunction, which is independent of dopaminergic degeneration and linked to key non-motor symptoms, particularly depression. These findings provide novel insights into the pathophysiology of PRKN-PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07693-2","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:58:34Z","timestamp":1769651914000},"page":"3960-3972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9708-9886","authenticated-orcid":false,"given":"Edoardo Rosario","family":"de Natale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-0241","authenticated-orcid":false,"given":"Heather","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6651-9994","authenticated-orcid":false,"given":"Joji P.","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-0592","authenticated-orcid":false,"given":"Eoin","family":"Mulroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas","family":"Antoniadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1699-9114","authenticated-orcid":false,"given":"Alana","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-1982","authenticated-orcid":false,"given":"Francesco","family":"Cavallieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7880-9921","authenticated-orcid":false,"given":"Micol","family":"Avenali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-0095","authenticated-orcid":false,"given":"Pasquale","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-6708","authenticated-orcid":false,"given":"Varvara","family":"Valotassiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-6687","authenticated-orcid":false,"given":"Eugenii A.","family":"Rabiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-394X","authenticated-orcid":false,"given":"Stephen","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-4482","authenticated-orcid":false,"given":"Nicola","family":"Tambasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6217-313X","authenticated-orcid":false,"given":"Maria Teresa","family":"Pellecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-3588","authenticated-orcid":false,"given":"Georgia","family":"Xiromerisiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8110-2005","authenticated-orcid":false,"given":"Vicky L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-7116","authenticated-orcid":false,"given":"Esther","family":"Sammler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-6820","authenticated-orcid":false,"given":"Enza Maria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-1692","authenticated-orcid":false,"given":"Franco","family":"Valzania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-286X","authenticated-orcid":false,"given":"Kailash P.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-7113","authenticated-orcid":false,"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"7693_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/bs.pbr.2020.11.001","volume":"261","author":"ER de Natale","year":"2021","unstructured":"de Natale ER, Wilson H, Politis M. Serotonergic imaging in parkinson\u2019s disease. Prog Brain Res. 2021;261:303\u201338.","journal-title":"Prog Brain Res"},{"issue":"2","key":"7693_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/bpa.12168","volume":"25","author":"K Seidel","year":"2015","unstructured":"Seidel K, Mahlke J, Siswanto S, Kr\u00fcger R, Heinsen H, Auburger G, et al. The brainstem pathologies of parkinson\u2019s disease and dementia with lewy bodies. Brain Pathol. 2015;25(2):121\u201335.","journal-title":"Brain Pathol"},{"issue":"1","key":"7693_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in parkinson\u2019s disease. Brain Res. 1990;510(1):104\u20137.","journal-title":"Brain Res"},{"key":"7693_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0079-6123(08)00902-3","volume":"172","author":"V Di Matteo","year":"2008","unstructured":"Di Matteo V, Di Giovanni G, Pierucci M, Esposito E. Serotonin control of central dopaminergic function: focus on in vivo Microdialysis studies. Prog Brain Res. 2008;172:7\u201344.","journal-title":"Prog Brain Res"},{"issue":"Pt 1","key":"7693_CR5","first-page":"120","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, et al. Preferential loss of serotonin markers in caudate versus putamen in parkinson\u2019s disease. Brain. 2008;131(Pt 1):120\u201331.","journal-title":"Brain"},{"issue":"10","key":"7693_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acn3.246","volume":"2","author":"C Buddhala","year":"2015","unstructured":"Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2015;2(10):949\u201359.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"7693_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","volume":"40","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al. Staging of serotonergic dysfunction in parkinson\u2019s disease: an in vivo 11\u00a0C-DASB PET study. Neurobiol Dis. 2010;40(1):216\u201321.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"7693_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.24859","volume":"81","author":"G Pagano","year":"2017","unstructured":"Pagano G, Niccolini F, Fusar-Poli P, Politis M. Serotonin transporter in parkinson\u2019s disease: A meta-analysis of positron emission tomography studies. Ann Neurol. 2017;81(2):171\u201380.","journal-title":"Ann Neurol"},{"issue":"1","key":"7693_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41531-024-00677-3","volume":"10","author":"PJ Menon","year":"2024","unstructured":"Menon PJ, Sambin S, Criniere-Boizet B, Courtin T, Tesson C, Casse F, et al. Genotype-phenotype correlation in PRKN-associated parkinson\u2019s disease. NPJ Parkinsons Dis. 2024;10(1):72.","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"7693_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00702-024-02833-8","volume":"131","author":"KG Jer\u010di\u0107","year":"2024","unstructured":"Jer\u010di\u0107 KG, Bla\u017eekovi\u0107 A, Borove\u010dki S, Borove\u010dki F. Non-motor symptoms of Parkinson`s disease-insights from genetics. J Neural Transm (Vienna). 2024;131(11):1277\u201384.","journal-title":"J Neural Transm (Vienna)"},{"issue":"16","key":"7693_CR11","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1097\/00001756-199911080-00025","volume":"10","author":"JM Horowitz","year":"1999","unstructured":"Horowitz JM, Myers J, Stachowiak MK, Torres G. Identification and distribution of parkin in rat brain. NeuroReport. 1999;10(16):3393\u20137.","journal-title":"NeuroReport"},{"issue":"1","key":"7693_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1471-4159.2007.04741.x","volume":"103","author":"Y Ren","year":"2007","unstructured":"Ren Y, Feng J. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J Neurochem. 2007;103(1):303\u201311.","journal-title":"J Neurochem"},{"issue":"1","key":"7693_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.expneurol.2009.12.021","volume":"222","author":"N Pavese","year":"2010","unstructured":"Pavese N, Moore RY, Scherfler C, Khan NL, Hotton G, Quinn NP, et al. In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol. 2010;222(1):120\u20134.","journal-title":"Exp Neurol"},{"issue":"6","key":"7693_CR14","first-page":"685","volume":"57","author":"M Filip","year":"2005","unstructured":"Filip M, Frankowska M, Zaniewska M, Go\u0142da A, Przegali\u0144ski E. The serotonergic system and its role in cocaine addiction. Pharmacol Rep. 2005;57(6):685\u2013700.","journal-title":"Pharmacol Rep"},{"issue":"12","key":"7693_CR15","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"Pt 10","key":"7693_CR16","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/brain\/awf237","volume":"125","author":"NL Khan","year":"2002","unstructured":"Khan NL, Brooks DJ, Pavese N, Sweeney MG, Wood NW, Lees AJ, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain. 2002;125(Pt 10):2248\u201356.","journal-title":"Brain"},{"issue":"15","key":"7693_CR17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder Society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"issue":"11","key":"7693_CR18","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","volume":"19","author":"M Visser","year":"2004","unstructured":"Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in parkinson\u2019s disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306\u201312.","journal-title":"Mov Disord"},{"issue":"6","key":"7693_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","volume":"73","author":"KR Chaudhuri","year":"2002","unstructured":"Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. The parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629\u201335.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2 Pt 1","key":"7693_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1288\/00005537-198402000-00004","volume":"94","author":"RL Doty","year":"1984","unstructured":"Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94(2 Pt 1):176\u20138.","journal-title":"Laryngoscope"},{"key":"7693_CR21","unstructured":"Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory II. San Antonio TX. Psychological Corporation"},{"issue":"3","key":"7693_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"7693_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive Assessment, moca: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"16","key":"7693_CR24","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1021\/jm000079i","volume":"43","author":"AA Wilson","year":"2000","unstructured":"Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43(16):3103\u201310.","journal-title":"J Med Chem"},{"issue":"1","key":"7693_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.neuroimage.2010.01.072","volume":"51","author":"RA Heckemann","year":"2010","unstructured":"Heckemann RA, Keihaninejad S, Aljabar P, Rueckert D, Hajnal JV, Hammers A. Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation. NeuroImage. 2010;51(1):221\u20137.","journal-title":"NeuroImage"},{"issue":"5","key":"7693_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","volume":"10","author":"J Logan","year":"1990","unstructured":"Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11\u00a0C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"7693_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nucmedbio.2004.10.001","volume":"32","author":"SJ Kish","year":"2005","unstructured":"Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol. 2005;32(2):123\u20138.","journal-title":"Nucl Med Biol"},{"issue":"11","key":"7693_CR28","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1097\/00004647-200111000-00010","volume":"21","author":"N Ginovart","year":"2001","unstructured":"Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab. 2001;21(11):1342\u201353.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"7693_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","volume":"112","author":"M Plotkin","year":"2005","unstructured":"Plotkin M, Amthauer H, Klaffke S, K\u00fchn A, L\u00fcdemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm (Vienna). 2005;112(5):677\u201392.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"7693_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/77060","volume":"25","author":"H Shimura","year":"2000","unstructured":"Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25(3):302\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"7693_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00018-015-2087-8","volume":"73","author":"A Hamacher-Brady","year":"2016","unstructured":"Hamacher-Brady A, Brady NR. Mitophagy programs: mechanisms and physiological implications of mitochondrial targeting by autophagy. Cell Mol Life Sci. 2016;73(4):775\u201395.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"7693_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.200809125","volume":"183","author":"D Narendra","year":"2008","unstructured":"Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795\u2013803.","journal-title":"J Cell Biol"},{"issue":"4","key":"7693_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tibs.2020.11.007","volume":"46","author":"AB Malpartida","year":"2021","unstructured":"Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial dysfunction and mitophagy in parkinson\u2019s disease: from mechanism to therapy. Trends Biochem Sci. 2021;46(4):329\u201343.","journal-title":"Trends Biochem Sci"},{"issue":"18","key":"7693_CR34","doi-asserted-by":"publisher","first-page":"18614","DOI":"10.1074\/jbc.M401135200","volume":"279","author":"JJ Palacino","year":"2004","unstructured":"Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem. 2004;279(18):18614\u201322.","journal-title":"J Biol Chem"},{"issue":"1","key":"7693_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/157015911795016985","volume":"9","author":"Y Takamatsu","year":"2011","unstructured":"Takamatsu Y, Shiotsuki H, Kasai S, Sato S, Iwamura T, Hattori N, et al. Enhanced hyperthermia induced by MDMA in parkin knockout mice. Curr Neuropharmacol. 2011;9(1):96\u20139.","journal-title":"Curr Neuropharmacol"},{"key":"7693_CR36","doi-asserted-by":"publisher","first-page":"113811","DOI":"10.1016\/j.expneurol.2021.113811","volume":"345","author":"A Sharma","year":"2021","unstructured":"Sharma A, Bazylianska V, Moszczynska A. Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine. Exp Neurol. 2021;345:113811.","journal-title":"Exp Neurol"},{"issue":"8","key":"7693_CR37","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2967\/jnumed.109.063529","volume":"50","author":"MJ Ribeiro","year":"2009","unstructured":"Ribeiro MJ, Thobois S, Lohmann E, du Montcel ST, Lesage S, Pelissolo A, et al. A Multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. J Nucl Med. 2009;50(8):1244\u201350.","journal-title":"J Nucl Med"},{"issue":"1","key":"7693_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0304-3940(01)02529-0","volume":"323","author":"R Hilker","year":"2002","unstructured":"Hilker R, Klein C, Hedrich K, Ozelius LJ, Vieregge P, Herholz K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett. 2002;323(1):50\u20134.","journal-title":"Neurosci Lett"},{"issue":"15","key":"7693_CR39","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/mds.22817","volume":"24","author":"N Pavese","year":"2009","unstructured":"Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord. 2009;24(15):2260\u20136.","journal-title":"Mov Disord"},{"issue":"5","key":"7693_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1474-4422(17)30056-X","volume":"16","author":"DJ Wile","year":"2017","unstructured":"Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, et al. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol. 2017;16(5):351\u20139.","journal-title":"Lancet Neurol"},{"issue":"8","key":"7693_CR41","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1474-4422(19)30140-1","volume":"18","author":"H Wilson","year":"2019","unstructured":"Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019;18(8):748\u201359.","journal-title":"Lancet Neurol"},{"issue":"3","key":"7693_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nbd.2011.05.009","volume":"43","author":"M Politis","year":"2011","unstructured":"Politis M, Loane C, Wu K, Brooks DJ, Piccini P. Serotonergic mediated body mass index changes in parkinson\u2019s disease. Neurobiol Dis. 2011;43(3):609\u201315.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"7693_CR43","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/mds.28971","volume":"37","author":"S Prange","year":"2022","unstructured":"Prange S, Metereau E, Maillet A, Klinger H, Schmitt E, Lhomm\u00e9e E, et al. Limbic serotonergic plasticity contributes to the compensation of apathy in early parkinson\u2019s disease. Mov Disord. 2022;37(6):1211\u201321.","journal-title":"Mov Disord"},{"issue":"12","key":"7693_CR44","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/mds.22212","volume":"23","author":"I Boileau","year":"2008","unstructured":"Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with parkinson\u2019s disease: a preliminary PET study with [11\u00a0C]DASB. Mov Disord. 2008;23(12):1776\u201380.","journal-title":"Mov Disord"},{"issue":"21","key":"7693_CR45","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","volume":"75","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in Raphe and limbic structures. Neurology. 2010;75(21):1920\u20137.","journal-title":"Neurology"},{"issue":"6","key":"7693_CR46","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.pnpbp.2005.03.012","volume":"29","author":"KP Lesch","year":"2005","unstructured":"Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):1062\u201373.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"7693_CR47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/mds.28299","volume":"36","author":"E Yu","year":"2021","unstructured":"Yu E, Rudakou U, Krohn L, Mufti K, Ruskey JA, Asayesh F, et al. Analysis of heterozygous PRKN variants and Copy-Number variations in parkinson\u2019s disease. Mov Disord. 2021;36(1):178\u201387.","journal-title":"Mov Disord"},{"issue":"6","key":"7693_CR48","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/brain\/awab456","volume":"145","author":"W Zhu","year":"2022","unstructured":"Zhu W, Huang X, Yoon E, Bandres-Ciga S, Blauwendraat C, Billingsley KJ, et al. Heterozygous PRKN mutations are common but do not increase the risk of parkinson\u2019s disease. Brain. 2022;145(6):2077\u201391.","journal-title":"Brain"},{"issue":"1","key":"7693_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10072-010-0360-z","volume":"32","author":"JF Guo","year":"2011","unstructured":"Guo JF, Wang L, He D, Yang QH, Duan ZX, Zhang XW, et al. Clinical features and [11\u00a0C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early onset parkinsonism. Neurol Sci. 2011;32(1):35\u201340.","journal-title":"Neurol Sci"},{"issue":"1","key":"7693_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/01.WNL.0000148725.48740.6D","volume":"64","author":"NL Khan","year":"2005","unstructured":"Khan NL, Scherfler C, Graham E, Bhatia KP, Quinn N, Lees AJ, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 2005;64(1):134\u20136.","journal-title":"Neurology"},{"issue":"9","key":"7693_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/01.wnl.0000267844.72421.6c","volume":"69","author":"F Binkofski","year":"2007","unstructured":"Binkofski F, Reetz K, Gaser C, Hilker R, Hagenah J, Hedrich K, et al. Morphometric fingerprint of asymptomatic parkin and PINK1 mutation carriers in the basal ganglia. Neurology. 2007;69(9):842\u201350.","journal-title":"Neurology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07693-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:17:38Z","timestamp":1781630258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07693-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7693"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07693-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Health Research Authority (IRAS numbers: 279941 and 281131; REC references: 21\/LO\/0140 and 21\/LO\/0142), and authorization for administration of radioactive substances was granted by the United Kingdom Administration of Radioactive Substances Advisory Committee. The clinicaltrials.gov identifiers are NCT05518617 and NCT05516732, respectively.\u00a0All participants gave their written informed consent prior to any research activity according to the Declaration of Helsinki","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and concent to participate"}},{"value":"Dr. Joji P. Verghese is supported by a clinical research fellowship from the Michael J. Fox Foundation for Parkinson\u2019s research. Dr. Alana Terry is supported by a clinical research fellowship from Invicro Ltd. Dr Savvas Antoniadis was, at the time of the study, supported by a clinical research fellowship from Hoffmann-La Roche. Professor Marios Politis research is supported by Michael J. Fox Foundation for Parkinson\u2019s Research, City Electrical Factors, Hoffmann-La Roche, and Invicro Ltd; Professor Kailash P. Bhatia has received grant support from the Edmond J. Safra Movement Disorders Research Career Development Award (Grant ID: MJFF-023893), Parkinson\u2019s UK (Grant ID: G-2401), EPSRC, and the David Pearlman Charitable Foundation. He has received a stipend from the International Parkinson\u2019s disease and Movement Disorders Society as editor of MDCP journal and book royalties from Oxford University Press; Eugenii A. Rabiner is an employee of Perceptive Discovery London. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}